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Abstract
Despite considerable effort and significant therapeutic advances, age-related macular degeneration (AMD) remains the
commonest cause of blindness in the developed world. Progressive late-stage AMD with outer retinal degeneration currently
has no proven treatment. There has been significant interest in the possibility that cellular treatments may slow or reverse
visual loss in AMD. A number of modes of action have been suggested, including cell replacement and rescue, as well as
immune modulation to delay the neurodegenerative process. Their appeal in this enigmatic disease relate to their generic,
non-pathway-specific effects. The outer retina in particular has been at the forefront of developments in cellular regenerative
therapies being surgically accessible, easily observable, as well as having a relatively simple architecture. Both the retinal
pigment epithelium (RPE) and photoreceptors have been considered for replacement therapies as both sheets and cell
suspensions. Studies using autologous RPE, and to a lesser extent, foetal retina, have shown proof of principle. A wide
variety of cell sources have been proposed with pluripotent stem cell-derived cells currently holding the centre stage. Recent
early-phase trials using these cells for RPE replacement have met safety endpoints and hinted at possible efficacy. Animal
studies have confirmed the promise that photoreceptor replacement, even in a completely degenerated outer retina may
restore some vision. Many challenges, however, remain, not least of which include avoiding immune rejection, ensuring
long-term cellular survival and maximising effect. This review provides an overview of progress made, ongoing studies and
challenges ahead.
Introduction
Age-related macular degeneration (AMD) is the commonest
cause of blindness in the developed world. The number of
patients with currently non-treatable AMD is staggering,
being responsible for approximately half of the 370,000
people registered as blind or partially sighted in the UK
alone [1]. Late-stage AMD affects over 2.4% of the adult
population over 50 and 12% of those over 80 years. The
number of AMD cases is predicted to rise by one-third over
the next decade, totalling nearly 700,000 in the UK by 2020
and 1,300,000 by 2050, with healthcare costs rising to £16.4
billion during 2010–2020 [2]. Each year in the UK, it is
estimated that ~70,000 patients present with late AMD; half
with wet disease and half with dry [3]. AMD is a worldwide
disease and globally it is thought to affect over 8 million
people.
AMD is manifested fundoscopically in the early and
intermediate stages by the appearance of yellowish sub-
retinal deposits, called drusen deep to the retinal pigment
epithelium (RPE) in the macular retina. At this stage, the
effect on vision is relatively mild, although acuity in low-
contrast conditions is frequently affected. At least 15% of
patients progress however to the more advanced ‘wet’ and
‘dry’ forms of the disease. Dry AMD is characterised by
degeneration of the RPE and subsequently the overlying
photoreceptors. ‘Wet’ AMD is characterised by aberrant
choroidal blood vessel growth beneath or through the RPE,
affecting the function of the overlying neurosensory retina
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by vascular leak, haemorrhage and fibrosis with subsequent
outer retinal degeneration. Treatments are available and
evolving for wet AMD, most notably, anti-vascular endo-
thelial growth factor (VEGF) treatment [4]. However, there
are, as yet, no effective treatments to prevent progression of
the underlying disease processes and advancement of dry
AMD (Fig. 1). This partly relates to the fact that the disease
process is complex and multifaceted, with both environ-
mental and genetic risk associations and the interplay of a
variety of cellular abnormalities, including impaired
autophagy and chronic innate immune activation [5].
Similarly, outer retinal degenerations caused by mono-
genetic defects are now the commonest causes of blindness
in the working age group in the UK, with the macular
dystrophy, Stargardt disease being one of the commonest
[1]. It has several similarities to atrophic AMD, and
although many approaches are being considered, none are
licensed and proven as yet [6].
Gene therapy and a variety of other therapies are being
investigated as possible treatments for these diseases, but
they are unlikely to restore vision once photoreceptors loss
has occurred nor do they aim to restore the RPE [7].
Electronic retinal interface devices show promise for
navigative vision in patients with advanced disease, but the
level of resolution achievable is likely a long way from
foveal vision [8]. Similarly, although optogenetic approa-
ches, with the induced expression of variety of light sen-
sitive molecules most notably Channelrhodopsin on
ganglion cells (NCT02556736, NCT03326336), are being
investigated, high-resolution vision is again unlikely.
A variety of cellular regenerative therapies with a range
of cell types are being studied for the treatment of AMD and
other outer retinal conditions. Transplantation is perhaps the
most obvious mode of action and the idea of ‘young’ cells
restoring and replacing the old is a particularly alluring
concept. In advanced AMD, despite extensive outer retinal
degeneration, the inner retina with its intricate neural con-
nectivity and output via the ganglion cells to the brain, is
anatomically intact, allowing the realistic possibility that
cell replacement in the outer retina may restore vision [9].
AMD is thought to be principally a disease of the RPE/
Bruch’s membrane (BrM)/choriocapillaris (CC) complex
initially and therefore in patients who present with wet
AMD of recent onset where there are preserved photo-
receptors, RPE (+/− BrM+/− CC) replacement alone may
be enough. Conversely, in those with dry AMD and wet
Fig. 1 A 76-year-old female
patient presenting with dry
AMD. First seen in 2013 with a
visual acuity of logMAR 0.3 and
small areas of paracentral RPE
atrophy with surrounding drusen
(a). Her vision slowly
deteriorated to logMAR 1.0 over
3 years with increasing central
geographic atrophy (b).
Progression of central outer
retinal atrophy shown on
spectral domain optical
coherence tomography
(SDOCT) (c–f)
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disease of longer duration, there will be varying degrees of
accompanying photoreceptor atrophy (Fig. 2).
However, the appeal of cellular therapies also rests in
their potential multiple mechanisms of action and their
generic, non-disease-specific effects that are particularly
attractive in a disease like AMD. Cell therapies can rescue
host cells by the production of cytokines and neurotrophic
factors as well as altering the neurodegenerative process by
immunomodulatory effects [10, 11]. Treatment with
mesenchymal-derived cells, including mesenchymal stem
cells (MSCs), and umbilical tissue cells are specifically
being evaluated for these effects. Some of these cells may
also debatably stimulate the endogenous activation of in situ
stem cells, and hence their action may be multi-fold.
Similarly, recent evidence has also shown that transplanted
photoreceptor precursor cells can restore cellular and visual
function by cytoplasmic transfer to host cells rather than
purely cell integration and potentially the neuroprotective
effects of cellular therapies may be among their most
important function, including the stimulation of intrinsic
retinal repair processes [12, 13] (Fig. 3).
Progress has been rapid, and transplanted cells from a
range of types and sources have been shown to restore
visual function in animal models of human disease, and
some are in early-phase human trials. Indeed the eye is at
the forefront of cell-based therapies, being an ideal site to
evaluate their effects. This is particularly true for outer
retinal diseases, where the confined, relatively immune
privileged, easily observed and surgically accessible space
between the photoreceptors and RPE is a particularly
tractable place to inject and evaluate treatments. The ana-
tomical connections required for proposed cellular trans-
plantation are relatively simple for both RPE cells and
photoreceptors relative to other central nervous system
locations, and retinal imaging and functional assessment is
at an advanced level with cellular level imaging possible.
The number of cells required to provide measurable visual
function is potentially low, with as few as 25,000 cells
restoring some vision in murine disease, reducing the anti-
genic load and cell production logistics [14]. Intravitreal
injections are now an everyday part of clinical care and cells
delivered in this way could also have outer retinal effects by
paracrine-mediated mechanisms easing logistic concerns.
The history and ongoing efforts to produce an effective
method of regenerating the degenerate outer retina, and in
particular AMD is a compelling story covered by several
excellent reviews, which we draw upon [15–21]. Our aim in
this further review is to outline the wide-ranging progress
being made in the field and the future challenges that lie
ahead.
Historical perspective and background
RPE transplantation
The RPE is the name given to the monolayer of hexagonal-
shaped pigmented epithelial cells that underlie the neuro-
sensory retina. They grow on a specialised basement
membrane, BrM and tight junctions between the RPE cells
form the outer retinal blood barrier. The RPE is vital to the
survival and function of the photoreceptors, and in addition
to phagocytosing photoreceptor outer segments and recy-
cling retinol as part of the visual cycle, it has several
additional key functions, including polarised growth factor
secretion, nutrient transport, stray light absorption and
Fig. 2 Schematic diagram illustrating normal retina contrasted with the changes observed in dry AMD
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antioxidant functions. With age, the ability of the RPE to
phagocytose and remove toxic by-products of photo-
transduction reduces, resulting in the accumulation of toxic
material that in turn reduces the ability of the cell to func-
tion optimally. This process, coupled with other age-
associated changes in the RPE and BrM are key stages in
the development of AMD [5]. Clinical observations have
shown that in vivo the RPE has very limited ability to
regenerate and consequently degeneration of these cells
leads to photoreceptor death and irreversible blindness.
There are two potential roles of RPE cell transplantation
in AMD, namely replacement of RPE function and trophic
support to dying cells (reviewed by Alexander et al. [22]).
RPE transplantation was first shown to successfully rescue
photoreceptor death in rats with a defect in the ability of
RPE cells to phagocytose photoreceptor outer segment discs
secondary to a mutation in the transmembrane proto-
oncogene tyrosine-protein kinase MER gene (Royal Col-
lege of Surgeons (RCS) rats) in 1988. As well as phago-
cytosing shed outer segments RPE cells produce several
neurotrophic factors [23] and photoreceptor rescue can
occur distant to the transplanted cells, up to 1400 microns
away in one study [24]. They also produce VEGF, which is
trophic for the CC endothelium. Recent research has shown
that loss of the endothelial cells of the CC is one of the
earliest detectable events in AMD and because the RPE
relies on the CC for metabolic support, this loss may be the
trigger for progression to more advanced stages (reviewed
by Chirco et al. [25]). RPE transplant may potentially thus
trigger choroidal vascular endothelial regeneration.
Fig. 3 Potential multiple and
overlapping modes of action of
cellular therapies for AMD
Fig. 4 77-year-old female patient presenting with large submacular
haemorrhage secondary to acute wet AMD (a). She initially underwent
subretinal haemorrhage displacement surgery with vitrectomy, sub-
retinal tissue plasminogen activator and ranibizuamb and air that
although successful in terms of haemorrhage displacement revealed a
large submacular scar (colour image (b), and SDOCT (c). The patient
then underwent subretinal choroidal neovascular membrane removal,
and peripheral large RPE/choroidal graft with a 200 degree temporal
retinotomy. Postoperative appearance (d), with corresponding auto-
fluorescent image showing uniform normal autofluorescence (e) and
SDOCT with a perfused choroidal appearance visible (f)
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The concept of RPE transplantation was quickly trans-
ferred to human studies with autologous RPE sheet trans-
plantation in advanced wet AMD. Both macular relocation
surgery, whereby the neurosensory retina is relocated from
a fresh non-diseased area of RPE, and autologous RPE
patches from the peripheral retina have demonstrated that,
in selected cases, it is possible to restore vision long term in
patients with recent onset wet AMD, where irreversible
photoreceptor degeneration has not yet occurred [26–32]
(Figs. 4 and 5).
Photoreceptor transplantation
When irreversible photoreceptor loss has occurred in AMD,
combined RPE and photoreceptor transplantation will be
required. As mentioned, despite profound outer retinal
degeneration, the neurons of the inner nuclear layer survive
for extended time periods after photoreceptor degeneration
despite significant dendritic retraction and circuit remodel-
ling. Studies with retinal prosthetic devices have shown that
patients appear to retain a retinotopic map even after
extensive outer retinal degeneration if the retina can be
stimulated appropriately. Replacing degenerated photo-
receptors would be one way to do this. Transplanted cells
would only need to make one synaptic connection to the
bipolar cells. The synaptic remodelling that developed
during regeneration would need to reverse; however, it is
known that plasticity exists in this regard [33].
There have been two approaches to photoreceptor
replacement considered, namely disassociated photo-
receptor cells delivered as a suspension and retinal sheet or
micro-aggregate transplantation (reviewed by Seiler and
Aramant [34]).
Transplantation of dissociated cells
The first transplants with disassociated neural retinal cells
into the subretinal space were carried out in light damaged
and RCS rats [35, 36]. Transplanted cells degenerated over
time without benefit. A key discovery, however, was made
in 2006, when young and immediately post-mitotic photo-
receptor precursors rather than retinal progenitor cells
(RPC), which are still in the proliferation phase or mature
adult cells, were identified as the most successful cell-type
for transplantation. Experiments showed that these cells
were capable of long-term survival, maturation and visual
improvement following transplantation into murine models
of retinal degeneration [14, 37–40]. Adult photoreceptors
can still integrate, but in significantly reduced numbers and
with markedly reduced survival rates in vitro as well, pos-
sibly partly related to the mechanical and enzymatic dis-
association required to prepare them [41].
Until recently, it was thought that donor photoreceptors
were able to physically migrate and integrate into the reci-
pient outer nuclear layer based on studies using immuno-
fluorescent (IF) labelling of proteins that could only
Fig. 5 A 78-year-old male
patient presenting with large
submacular haemorrhage and
extensive choroidal neovascular
membrane in his right eye (a),
having already lost vision in his
left eye with an established
disciform scar (b). Patient
underwent macular relocation
surgery with a 360 degree
peripheral retinotomy and
CNVM removal, and subsequent
counter rotation surgery with
visual improvement (c). Note
scar (white arrow) from previous
CNVM now eccentric to fovea
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originate from the donor. However, recent studies have
suggested that this is a relatively rare event in animals with
some degree of photoreceptor preservation, and instead
there appears to be some form of cytoplasmic exchange
between the donor and host cells to account for the IF
findings [12, 13, 39, 42–44]. However, in this review, for
simplicity, we will continue to refer to ‘integration’ of
photoreceptors even if this is not always the actual
mechanism for disease rescue.
Retinal sheet transplant
Another way to transplant photoreceptors is as part of full
thickness retinal sheet, ideally when they are about to start
forming their synaptic connections, and when considerable
plasticity exists (reviewed by Seiler and Aramant [34]).
Indeed, foetal retinal tissue has been shown to be able to
connect to mature neural tissue after transplantation into the
brain [45]. Foetal retina also has lower immunogenicity
containing less microglia (which migrate into human foetal
retina from 16 weeks), fewer blood vessels and lower
numbers of surface antigens than adult tissue [46–48]. In
initial experiments in the early 1990s using microaggregates
of retinal tissue, better preservation and growth of outer
segments, albeit in rosettes, was demonstrated after trans-
plantation into the subretinal space of RD1 mice as com-
pared to single cells [49, 50]. Full thickness retinal sheets
(including with attached RPE) have also been evaluated and
shown to integrate with a degenerating retina and restore
visual responses as shown in several rat models of retinal
degeneration [51–53]. One of the problems of sheet trans-
plantation is that sheet orientation is clearly important, but
also budding photoreceptors axons have to migrate through
the donor inner retina to reach the host bipolar cells. Partial
thickness retinal sheets sectioned down to the photoreceptor
layer using a vibratome or excimer laser have therefore also
been evaluated [54–57], but these manoeuvres did not seem
to improve connectivity and had lower transplant survival
rates than full thickness grafts [57] probably relating to
trauma.
Several patients have been treated with foetal retinal
transplants delivered as microaggregates or sheets [58–60].
A Phase II trial was conducted in a group of ten patients (six
with RP and four AMD) between 2002 and 2005 [61].
Vision improvement occurred in some patients and inter-
estingly started about 6 months after surgery, corresponding
to the time expected for the foetal cells to develop into
functional photoreceptors and suggesting that the effectivity
observed was not a short-term trophic effect.
In human trials, sheet transplants seem to have longer
survival that microaggregates and probably single cells; a
foetal retinal graft sheet in a clinical trial was observed to
survive 3 years after the transplantation, while transplants in
the form of microaggregates were no longer able to be
detected [62]. However, systematic comparisons of photo-
receptor sheets vs. suspension transplants in humans have
not been published and it is not known whether one
approach is better than the other regarding visual outcome
or transplant survival.
The optimum age of foetal donor tissue for both sheet
and single-cell photoreceptor transplants for these approa-
ches is in the second trimester with obvious ethical and
supply problems. Other sources of cells have therefore been
sought and these are discussed later.
Rescue of degenerating cells using cells of non-
neural lineage
A variety of cell types have been shown to rescue photo-
receptors in preclinical models of human retinal degen-
erative disease, including bone-marrow-derived
hematopoietic and MSCs, adipocyte-derived cells, umbili-
cal tissue cells and neural progenitor cells (NPCs).
Although bone-marrow-derived MSCs can differentiate into
cells expressing photoreceptor proteins when injected into
the subretinal space, their ability to differentiate into func-
tionally useful retinal cells is under debate. Their action is
thought to be largely related to paracrine effects from
neurotrophic factors (NTF) production. NTF are a family of
proteins that participate in the regulation of the develop-
ment, function, and survival of neurons and other cells in
the nervous system [63, 64]. Early-phase clinical trials with
encapsulated RPE cells producing ciliary neurotrophic
factor (CNTF) suggested some photoreceptor protection in
patients with retinal degeneration [65–67]. Although the
effect of most factors on photoreceptor survival is indirect
via microglia and Müller cells [68], red-green cones express
the brain-derived neurotrophic factor (BDNF) receptor trkB
and can directly respond to BDNF [69]. Transplants of rods
in murine degeneration models slow cone degeneration
[70]. This so-called rod-derived cone viability factor is a
diffusible factor, synthesised by rods, and distinct from
other known trophic factors [71].
As mentioned previously, RPE cells may also exert a
significant effect on photoreceptor regeneration and survival
by trophic effects alone, thought largely to be due to the
production of pigment epithelium-derived factor (PEDF).
Delivery of cells to a subfoveal location requires foveal
detachment, which could compromise the vision of the
patient, particularly in the setting of retinal degenerative
disease. Transplantation of NPCs subretinally has, however,
demonstrated that they can migrate from the subretinal
injection site quite extensively [72, 73], allowing the pos-
sibility that extrafoveal transplantation of some of these
rescue cell types will have a more direct foveal effect not
only from trophic factor release but also cell migration.
V. Chichagova et al.
Many of these classes of cells also display variable
immunomodulatory activities. The most well established is
the suppression of immune responses and inflammation by
bone-marrow-derived MSCs. Under various conditions,
MSCs induce the expression of immune-modulatory pro-
teins, including Ym1, insulin-like growth factor-1 (IGF-1),
Th2-related cytokines, galectin-3, and class II major histo-
compatibility complex (MHC) antigens [74]. However,
untreated MSCs in an in vitro rat retina-explant model
transdifferentiated into microglial cells [75] and non-
autologous MSC transplantation may induce an inflamma-
tory reaction.
The potential for in situ regeneration
Many species of amphibians and fish have a remarkable
ability to regenerate damaged retinas. The source of cells for
this appears to come from three main sources of resident
stem cells dependent on species and age; the anterior retina
in the ciliary margin zone, Muller cells (MC), and RPE [76–
80]. Humans do not have these abilities; however, inter-
estingly, the mammalian MC transcriptome overlaps sig-
nificantly with that of RPCs and in vitro studies have
identified a population of human MCs that are able to
develop into retinal neurons, including those with photo-
receptor markers [81–83]. Furthermore, on transplantation
into a rodent model of photoreceptor degeneration, these
MC-derived photoreceptor-like cells were able to migrate
and integrate into the host outer nuclear layer, leading to an
improvement in photoreceptor function as assessed by
electroretinography [78]. The feasibility of such an ex vivo
approach, however, is limited by their limited ability to self-
renew and differentiate in vitro, their yet undetermined
capacity to generate mature retinal neurons as well as donor
tissue availability. If, however, the signalling pathways that
regulate differentiation of these cells into desired pheno-
types (e.g., photoreceptors, RPE) could be identified, a
future hope would be that cell replacement could be initi-
ated endogenously via gene reprogramming and differ-
entiation of adult stem cells in situ. Indeed, recently, Jorstad
et al. showed that by overexpression of the proneural
transcription factor Ascl1 combined with the use of a his-
tone deacetylase inhibitor, which altered the epigenetic
profile of the MC genome, adult mice were able to generate
retinal neurons from MCs in situ after retinal injury [84].
Sources of cells for transplantation
A wide variety of exogenous cell sources for transplantation
have been considered and are listed in Table 1. They can be
broadly divided into adult tissue-derived stem cells, foetal-
Table 1 Cell sources for transplantation
Category Type Current or previous human trials in AMD?
Autologous ocular tissue RPE patch +/− Bruch’s
membrane and choroid
Yes [26, 27, 85, 86]
Peripheral RPE as suspension Yes [87]
Iris pigment epithelium Yes as cell suspension [88–90]
Foetal Neuroretina Yes as cells suspension and
microaggregates [58, 59]
RPE sheet Yes [91, 92]
Combined RPE and retinal sheet Yes [61, 93]
Retinal progenitor cells Yes—See Table 2
Adult stem cells RPE To date only as an allograft of unsorted
adult RPE [94, 95]
Muller cells Not as yet
Ciliary margin zone stem cells Not as yet
Mesenchymal stem cells Yes—intravitreal and subretinal
Table 2
Adipose-derived cells Yes—Intravitreal
(Table 2).
Umbilical tissue cells Yes—cell suspension subretinally
delivered via transchoroidal route
(Table 2).
Embryonic stem cells Differentiated to all retinal cell
types
Yes as RPE cell suspension and sheet
(Table 2).
Induced pluripotent stem
cells
Differentiated to all retinal cell
types
Yes as cell sheet
Table 2
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derived progenitor cells and pluripotent stem cell-derived
cells. A summary of current and recent clinical trials is
shown in Table 2.
For photoreceptor cells, as described above, the devel-
opmental stage and the environment the cells are grown in
are vital to their ability to fully develop after transplantation
and to engraft into the retina. Pluripotent stem cells (PSCs)
are currently considered to be the optimum cell source for
these but the potential of foetal-derived RPC will also be
discussed.
PSCs could also provide a ready source of RPE cells.
However, in contrast to photoreceptor transplants, trans-
planted RPE cells, virtually regardless of age or origin,
readily extend apical villous process around host photo-
receptors and phagocytose shed outer segment discs [15].
Autologous RPE cells from the peripheral retina are a viable
source, but current methodologies of autologous transplan-
tation require major surgery with significant risk and side
effects and variable results. At least some of the variability
relates to surgical trauma to the RPE from the donor site, as
well as senescence and disease-carrying gene variants and as
such alternative cell sources have been sought.
Iris pigmented epithelial cells
Iris pigmented epithelial (IPE) cells are derived from the
same embryonic cell line as RPE and are similar in many
respects to RPE cells with apical/basal polarisation,
microvilli, and the same type of tight junctions. Their
appeal lies in the fact that they can be easily collected by
surgical iridectomy and so could be autologous [85–90].
There are, however, several functional differences, although
it is possible that IPE cells could acquire RPE properties
when transplanted into the subretinal space in patients with
AMD. Gene expression for intra- and extracellular retinal-
binding proteins, which are essential for the visual cycle is
lower in IPE cells than RPE cells [88]. In vitro IPE cells,
although able to phagocytose photoreceptor outer segments,
are less able to degrade them compared with RPE cells [89].
The level of expression of VEGF is also lower in IPE cells
than in RPE cells [90], which may have consequences on
choroidal restoration/health after transplantation but may
also be beneficial in the context of wet AMD [85]. Sus-
pensions of IPE have been evaluated in clinical trials with
possible modest improvements in vision [91–93]. Ulti-
mately, however, they suffer from the problems of senes-
cence and the same disease-carrying genetic profile of the
autologous donor.
Foetal and adult RPE
Foetal RPE overcomes the problems of senescence but has
obvious problems of ethical acceptability and supply.
However, the recent finding that the human RPE contains a
small subpopulation of cells that can self-renew and act as
adult RPE stem cells [94] capable of producing large
numbers of ‘new’ RPE cells is an exciting development [94,
95]. Transplantation of these created allogeneic RPE res-
cued vision in the RCS rat in a differentiation stage-
dependent manner. Specifically, transplantation of an
intermediate 4-week stage of RPE differentiation most
consistently preserved vision compared to older or younger
RPE cells [95].
Foetal retinal progenitors
In vivo RPC exit the cell cycle and start differentiating into
photoreceptors between 14 and 20 weeks of gestation and
aside from ethical concerns, they would appear to offer a
feasible source of cells for photoreceptor replacement. They
also have relatively low immunogenicity and are not always
rejected. Several studies have evaluated the use of dis-
associated foetal RPC for cellular transplantation [96] and at
least two lines have been developed commercially and are
in phase 1/2 studies in patients with photoreceptor dystro-
phies. ReNeuron have developed an interesting technology,
whereby foetal RPC can be expanded at least 40-fold in
hypoxic conditions akin to that experienced in vivo, over-
coming many of the supply problems in obtaining these
cells from week 16 to week 18 human foetuses. Publica-
tions have suggested that in vitro expanded RPC have some
ability to differentiate and express photoreceptor markers
[97–99], but this is limited and differentiation after trans-
plantation appears to be dependent on host conditions par-
ticularly maturity, with transplant into immature retinas
being more successful than mature ones [100−102]. Fur-
thermore, cell migration into the outer retina is variable and
the predominant markers expressed by transplanted cells are
glial [103]. It is possible, however, that differentiation,
migration and survival can be improved by alterations in
delivery and the host environment [104, 105] and further-
more trophic and cytoplasmic transfer mechanisms still
make these cells lines a potentially effective regenerative
strategy.
Pluripotent stem cells
Human PSCs can produce all the cell types needed for
retinal regeneration (reviewed by Borooah et al. [106]).
They are emerging as the preferred cell source because of
their accessibility, expansion ability, and their ability to
mimic retinal development with all its complexity to pro-
duce cells of the exact developmental stage required.
The umbrella term PSC is most commonly used to
describe two types of stem cells: embryonic stem cells
(ESCs) and induced pluripotent stem cells (iPSCs). Both are
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defined by two key properties, namely an indefinite self-
renewal ability and the capacity to give rise to any adult
somatic cell type [107] (Fig. 6).
Human ESCs (hESCs) are derived from the inner cell
mass of a preimplantation blastocyst. Several lines have
been created since their discovery in 1998 and used to
understand the mechanisms behind human embryonic
development and congenital disease [108]. The use of hESC
for research purposes is surrounded by a number of ethical
issues and their use is prohibited in several countries. Their
differentiated progeny express human leucocyte antigens
(HLAs) that could result in graft rejection after transplan-
tation, although this could be overcome by the creation of
HLA-typed hESC banks, from which a best match could be
selected for each transplant recipient.
In 2006, Yamanaka and Takahashi, building on the work
of Gurdon, isolated four key transcription factors (gene
expression ‘controllers’) that when expressed exogenously
in somatic cells induced the formation of pluripotent cells in
a process termed reprogramming [109, 110]. These
‘induced’ pluripotent stem cells (iPSC) share properties
with ESCs, including the ability to self-renew and to be
differentiated into the three germ layers [111]. Importantly,
they can provide a source of autologous stem cells without
the ethical concerns of ESCs. iPSCs not only provide a
source of cells for transplantation but also present a unique
opportunity to create in vitro disease models [112, 113],
which can be used to understand disease pathology and
drug discovery; particularly useful for retina where avail-
ability of patient-specific cells (i.e., photoreceptors and
RPE) is only possible with invasive surgery or post mortem.
Challenges still remain in finding the optimum strategy to
ensure complete reprogramming (which can affect differ-
entiation ability), maximising efficiency and minimising
genetic changes during and after the process, but progress
has been rapid and the technology is advancing at a pace.
Being autologous, however, also creates a potential pro-
blem for transplantation in that the cells will carry the same
disease-causing gene mutations of the patient. This might not
always be a problem in some diseases, particularly AMD,
where onset is in later life, but even then gene editing may be
useful to enhance integration or reduce recurrence. Current
gene therapy approaches in the context of a patient with a
known gene mutation uses viral vectors to transfect a cor-
rected copy of the gene and a suitable promoter either in the
cytoplasm or a ‘safe’ site in the genome in either the RPE or
retinal cell type affected. These cells, being mature and non-
dividing, only need this transfection event to occur once for
prolonged protein expression. Conversely, in a PSC-derived
cell line being delivered for transplantation, the optimum way
of carrying out gene therapy would be to edit the genome at
the PSC stage, to precisely correct for the mutation, thus
correcting all derived differentiated cells thereafter. New
gene editing technologies use specifically designed site-
specific restriction endonucleases, such as Zinc Finger
Nucleases (ZFNs), Transcription Activator-Like Effector
Nucleases (TALENs), and clustered regularly interspaced
short palindromic repeat/CAS9 RNA guided nucleases
(CRISPR/Cas) [114−116] to excise the mutant part of the
gene and simultaneously deliver a corrected copy, which then
integrates into the cleavage point by homologous
recombination.
Fig. 6 Schematic diagram
showing the sources, and retinal
differentiation potential of
human pluripotent stem cells.
Embryonic stem cells are
derived from the inner cell mass
of a pre-implantation embryo.
Pluripotency can be induced in
adult somatic stem cells by the
delivery of key transcription
factors that reprogramme the
cells (delivered in illustration by
non-integrating Sendai viruses)
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The use of PSC also carries another concern namely
tumour formation. Transplantation of undifferentiated ESC
and iPSC, which could exist in a differentiating colony, can
result in teratoma formation. In one study, transplantation of
ESC-derived neural precursors into the subretinal space of a
mouse model of RP resulted in teratoma formation in 50%
of the mice within 8 weeks [117]. Sorting for markers that
identify these remaining pluripotent cells, including TRA-1-
60 and SSEA1 before transplantation is one way to reduce
the risk of this. Yamanaka used four transcription factors
OCT4, SOX2, KLF4 and c-MYC to reprogram cells and
inserted these into the genome using an integrating
retrovirus-derived vector. C-Myc is a potent oncogene and
the process of transcription factor insertion and expression
can cause genome mutations and dysfunction. Furthermore,
human ESC-derived cell lines can exhibit phenotypic
instability or develop altered gene expression, including
variable X-inactivation with serial passaging in culture.
Alternative strategies have been developed with the view of
bypassing some of the issues outlined above. Protocols for
reprogramming without c-Myc and using various combi-
nations of other transcription factors have been tested [118].
Additionally, alternative methods exist that use non-
integrative approaches, such as RNA-based Sendai virus,
and non-viral delivery systems, including episomal vectors,
messenger RNA and recombinant proteins with varying
efficiency. Whatever the system chosen, ongoing vigilance
is essential to detect chromosomal and genetic alterations in
the cells used. Indeed, recently, an iPSC-RPE transplant
trial was halted partly related to the finding of genetic
changes in the iPSC-derived cell line. Three genes had been
deleted, and there were mutations in three further genes,
including one oncogene. However, reassuringly in the one
patient treated in this trial and the patients treated in a large
completed ESC-RPE transplantation trial, there have been
no tumours reported [119, 120].
A third type of autologous PSCs can be produced by
cloning. In this technique, termed somatic cell nuclear
transfer, the nucleus of a donor adult somatic cell is trans-
planted into an enucleated oocyte to produce a near geneti-
cally identical cell to the original adult nuclear donor, akin to
an ESC and as used subsequently to produce ‘Dolly the
sheep’ [121]. These ESCs produced by nuclear transfer are
more difficult to generate than iPSCs; however, the ability of
the technique to replace aged or diseased mitochondria and
the fact that they appear to be closer in terms of epigenetic
and transcriptomic profiles to ESC may make this a useful
approach for some applications in the future [122].
Differentiation towards RPE and photoreceptors
On the basis of early publications describing differentiation
of hESCs, all retinal cell types have now been differentiated
from human iPSCs (hiPSC). Differentiation models devel-
opment in vivo in which the initial cell mass, representing
the epiblast divides into the three embryonic germ layers
before the ectoderm differentiates further into neuroecto-
derm then retinal cell types [123−126]. At a cellular level,
PSCs undergo stepwise differentiation through neural and
retinal progenitor stages before differentiating to either RPE
or neuroretinal cell types, all of which can be detected by
specific immunofluorescent markers. Cells following an
RPE fate show increasing MITF expression and neuro-
retinal cells CHX10 expression, followed by cone-rod
homeobox protein (Crx) and Recoverin expression as they
develop into photoreceptors. In human PSCs, this process
takes several months depending on culture conditions with
cone markers appearing before rods [127, 128].
In vitro retinal differentiation protocols for PSCs can be
broadly divided into default differentiation, in which cells
differentiate to retinal lineages in the absence of extrinsic
growth factors [129] and directed differentiation protocols,
in which extrinsic transcription factors, proteins, and small
molecules are added to direct the differentiation pathway
along a specific course in a more efficient process both in
terms of cell specificity and time course. Directed differ-
entiation protocols are based on knowledge of basic prin-
ciples of developmental neurobiology. It is known that
retinal differentiation is controlled by a diverse set of sig-
nalling pathways that affect the identity of the resulting cell
population. As a result, various exogenous factors have
been used to direct the differentiation towards the desired
retinal cell type. A number of studies have highlighted the
importance of TGFβ, BMP, Wnt and Nodal signalling
pathways in retinal fate commitment. Various research
groups have used a combination of small molecules and
recombinant proteins targeting these pathways in their dif-
ferentiation protocols, including SB431542, Noggin,
DKK1, LEFTY-A and Activin A [125, 130–132]. IGF1 has
also been shown to augment differentiation towards RPE
and neural retina [123, 128]. Some groups have investigated
the effect of culture conditions on RPE differentiation,
including using different growth substrates [133, 134]. The
level of oxygen during differentiation has also been inves-
tigated as a possible modulator in cell differentiation. There
is some evidence that hypoxic conditions during stem cell
culture lead to favourable outcome in neuroectodermal and
retinal differentiation [135−137].
iPSC lines vary greatly in their ability to differentiate into
RPE and photoreceptors. These differences can be attrib-
uted to multiple factors. Variation in endogenous gene
expression controlling differentiation have been shown to
be one of the factors [138, 139], in which case a more
tailored approached to differentiation protocols design may
be required. Mutations in mitochondrial DNA are believed
to introduce additional variability [140]. Other factors that
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have been shown to contribute to differentiation efficiency
include DNA methylation, epigenetic memory, genetic
background of hPSCs, and X chromosome inactivation,
potentially leading to increased expression of oncogenes
(reviewed by Ortmann et al. [141]). Recently, significant
effort has been made towards driving PSCs towards a so-
called ‘naive’ ground state, which is believed to be
the only true totipotent type of cell with no differentiation
bias. However, so far many studies have only partially
managed to recapitulate ground state requiring additional
study [142].
Three-dimensional retinal culture
A major leap forward in photoreceptor differentiation was
made in 2011 when Eiraku et al. showed that by suspending
developing PSC in 3D culture conditions, the retina could
be observed to arise from a neuroectodermal structure
mimicking the anterior part of the primitive forebrain, with
optic grooves protruding to form optic vesicles, and then
invaginating spontaneously (rarely) to form a double walled
optic cup structure, without the requirement for surface
ectoderm [143]. Several laboratories have replicated this
work now with hiPSC [128, 144–146] and the retinal
‘organoids’ produced shown to replicate the organised ret-
inal lamination seen in vivo with all key retinal cell types
identified and mature features observed, including photo-
receptor outer segments not seen in 2D cultures [146, 147].
The technology has great potential for optimising the
maturation of photoreceptor cells prior to transplantation,
offers the possibility of retinal sheet transplantation as well
as huge opportunities for improved disease modelling,
toxicology and drug testing (Fig. 7).
RPE characteristics
RPE cells can be easily recognised by their characteristic
pigmented polygonal appearance from an early stage in
culture and subsequently dissected out to purify and mature.
Their maturity can be assessed by a variety of morpholo-
gical, molecular and functional features. RPE-specific
markers include those for phagocytosis such as MERTK
and the basal marker BEST1. Apical membrane-associated
markers include Na+/K+ATPase. Visual cycle markers
include RPE65, LRAT and CRALBP [148]. Phagocytosis,
trans-epithelial resistance and apical (PEDF)/basal (VEGF)
polarity of growth factor secretion can all be tested as
measures of function. The optimum age for transplantation
Fig. 7 Retinal organoids with
adjacent RPE 3D differentiation
from human pluripotent stem
cells. Optic vesicles with
lamination (a). b–d show a
diagrammatic representation of
the laminated area with
schematic antibody labelling,
adjacent to actual antibody-
stained sections. b
Photoreceptors labelled with
CRX (green) and Recoverin
(red), c photoreceptors,
Recoverin (red), and retinal
ganglion cells, HuC/D (green), d
Muller glia (green)
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is uncertain but generally cells are used once mature RPE
markers are expressed.
Photoreceptor recognition
Being non-pigmented, photoreceptor cells suitable for
transplantation are less easy to identify. The intracellular
markers used in vitro to identify photoreceptors such as
CRX and NRL cannot be used to sort cells for transplan-
tation using fluorescent- or magnetic-activated cell sorting
[149]. Studies using animal models have sorted photo-
receptors using transgenic fluorescent protein expression
driven by promoters of photoreceptor genes; however, these
are unlikely to be acceptable for human studies. The cell
surface marker CD73 has been identified as marker for rod
photoreceptors isolated from foetal mice [150−153] and has
been shown to increase cell integration either alone [153] or
in combination with CD24 [152]. Similarly, a panel of
surface markers (CD73+/CD133+/CD24+/CD47+/CD15
−) [151] has been shown to increase integration rates in
mice compared to single-cell surface markers. The situation
is as yet less clear in human PSC-derived cells, although
Welby et al. have recently identified a cone biomarker panel
(SSEA1−, CD26+, CD133+, CD147+) that positively
enriches for human foetal L/M-opsin cones as well as a
stem cell-derived cone photoreceptor population [154].
Current PSC-derived retinal cells delivery
strategies in investigation
Successful cell replacement does not equate solely to the
ability to produce, and isolate the desired cell types, the
cells also have to be delivered successfully to the subretinal
space, survive and be able to replace the function of the
degenerated cells. We now discuss the various approaches
being evaluated to achieve this and the challenges faced.
RPE replacement
RPE replacement, in particular, using PSCs has progressed
relatively rapidly and two approaches are currently being
considered for their transplantation: RPE cell suspension
injection into the subretinal space and RPE sheet
transplantation.
RPE cell suspension
Suspension of RPE cells transplanted into the subretinal
space has rescued photoreceptors in numerous preclinical
models of retinal degeneration [155]. Ocata Therapeutics,
now Astellas, have carried out a number of phase I/II trials
to evaluate the use of subretinally delivered hESC-derived
RPE cell suspensions in patients with advanced dry AMD,
Fig. 8 A 45-year-old male
patient with Stargardt’s macular
dystrophy with symmetrical
atrophic maculae (a, b). Patient
underwent vitrectomy with
subretinal injection of a
suspension of embryonic stem-
cell-derived retinal pigment
epithelial cells with an injection
point superonasal to the foveal
centre (c). (Injection point
shown by black asterisk, area of
subretinal bleb produced
outlined by solid black line, with
small subretinal air bubble
indicated by white arrow: note
image is intraoperative view
with superior retina shown
inferiorly). Nine-month
postoperative appearance shows
areas of subretinal pigment in
the area of the original injection
(white circle) (d)
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Stargardt’s macular dystrophy and myopic macular degen-
eration. Systemic immunosuppression with tacrolimus and
mycophenolate was used. Reassuringly safety and toler-
ability were demonstrated, and some patients showed
improved vision in the injected eyes compared to the fellow
untreated eyes; however, the usefulness of RPE transplan-
tation in patients who already have poor vision owing to
secondary photoreceptor atrophy is unclear. Fundoscopy of
the patients showed gradually enlarging pigmented clusters
subretinally in the area of injection, which could represent
proliferating RPE cells but positive autofluorescence was
not shown questioning their viability and function (Fig. 8).
The clusters showed a predilection for focal areas of RPE
atrophy in some patients, suggesting preferential growth in
these areas but centrally in the area of gross atrophy there
was no pigmentation produced. One possible explanation
for this is that in AMD there are several abnormalities in
BrM, including thickening, protein crosslinking, non-
collagenous protein deposition, lipid deposition and
advanced glycation end-product formation. A reduction in
heparin sulphated proteoglycans [156] and an increase in
tenascin-C and the chondroitin sulphate proteoglycan
aggrecan, as well as a reduction in the levels of activated
MMP-2 and -9 have been described in AMD, which may be
responsible for some of the thickening seen related to
impaired matrix degradation [157, 158]. All these changes
result in a reduction in the normal integrins, the cell surface
ligands that bind ECMs, including laminin, fibronectin,
vitronectin, and which in turn affect the ability of trans-
planted RPE cells to adhere and form a monolayer, critical
to their function and survival.
Various possibilities have been suggested to counteract
this, including re-surfacing BrM to enhance RPE attach-
ment. Research by Priore and colleagues showed that
coating aged BrM with a mixture of laminin, fibronectin
and vitronectin significantly improved cell adhesion, sur-
vival and proliferation and phagocytosis [159−161].
Another approach is to increase the surface levels of
integrins. Long-term culture increases the expression
levels of a-integrins, which has a positive effect on RPE
cell adhesion to BrM [162]. Genetic manipulation can
also be used to overexpress specific integrins specific to
the altered BrM, and integrin function can also be modu-
lated by modifying their activation state, including with
manganese [158]. Ex vivo experiments using BrM from
human cadaver eyes with AMD have documented impaired
transplanted RPE survival in areas of RPE atrophy which
could be improved using bovine corneal endothelial cell-
conditioned media [163]. This was thought to work by
altering cell behaviour and survival and not by altering BrM
[163, 164]. Other ECMs and/or hydrogels could potentially
be used in the same way and simultaneously improve cell
distribution.
RPE sheet transplantation
Formation of a monolayer with apical-basal polarity and
attachment to a surface are critical to RPE cell function and
survival. Another approach to transplantation is, therefore,
to deliver RPE cells as an intact monolayer on a carrier to
replace BrM (reviewed by Hynes et al. and Delplace et al.
[165, 166]). Use of a sheet scaffold may also prevent the
BrM abnormalities from unfavourably altering the beha-
viour of the transplanted cells by acting as a barrier between
them and the pathological BrM surface. Many different
materials have been studied as potential BrM replacements.
Both biodegradable/non-biodegradable and synthetic/nat-
ural membranes have been suggested. Carr et al. [167] have
described the use of a vitronectin-coated polyester mem-
brane to deliver an RPE monolayer to the subretinal space,
while Lu et al. [168] used nanotechnology-manufactured
parylene C scaffolds for RPE transplantation. A variety of
other complex biomimetic non-biodegradable membranes
that closely mimic native BrM and appear to optimise RPE
cell growth and function have also been developed,
although for delivery they may require a more rigid carrier
[166]. Using electrospinning, various nanofibrillar materials
have been investigated, including silk [169], poly-
caprolactone [169], polyimide [170], a combination of silk
and polyethylene glycol [171], and an RGD-functionalized
polymethyl methacrylate-co-polyethylene glycol methacry-
late [172−174].
Two RPE sheet transplantation trials in humans are in
progress both in patients with wet AMD of recent onset and
both inserting RPE sheets grown from PSCs subretinally.
The London Project to Cure Blindness (https://clinicaltrials.
gov/ Identifier: NCT01691261) uses hESC-derived RPE on
a polyester sheet. The Riken Institute in Japan (JPRNU-
MIN000011929) used hiPSC-derived RPE transplanted on
its own type 4 collagen layer without the use of any artificial
scaffolds. The Riken trial has been halted partly due to
concerns regarding the genomic integrity in the donor cells
but has reported results in one patient to date. Safety and
tolerability have been shown and long-term cell survival
suggested by graft appearance at 6 months [120]. The
protocol is currently being revised to use HLA-matched
allogeneic iPSC-derived RPE cells [175]. Further results are
eagerly awaited.
It is useful also to reflect on some of the findings from
previous work using autologous RPE cell patches. Post-
operative proliferative vitreoretinopathy (fibrosis), induced
partly by the retinotomy site to introduce the patch was a
problem, but it is hoped that the avoidance of a donor
retrieval site in the eye will reduce this. Sheet transplanta-
tion requires a significantly larger incision than suspension
injection but multiple sheets rather than single large ones
could be transplanted to cover larger areas. Autologous
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work has also suggested that peripheral retinotomies may be
better tolerated than posterior ones as used in both of the
current sheet trials and this is something that could be
explored albeit with more extensive surgery required [176].
Another factor unaddressed at present is the role of a
choroidal circulation in RPE sheet transplants. Generally in
grafts for wet AMD, the area of choroidal neovascularisa-
tion is removed, which is accompanied by the adjacent
choroid. Autologous vascularised graft survival is highly
dependent on the re-establishment of a choroidal circulation
from the periphery of the graft [177]. It is unknown how
important this will be in non-vascularised RPE grafts. OCT
angiography may be particularly revealing in assessing this
aspect as has been used successfully with autologous RPE/
choroidal grafts [177].
Photoreceptor replacement and regeneration
To date, there have been no clinical studies with PSC-
derived photoreceptor cells, although this will likely
occur soon based on a number of compelling animal stu-
dies. Human trials have commenced with foetal-derived
RPC and previously carried out with foetal-derived retinal
sheets.
Ongoing developments in transplantation of
photoreceptors
Studies in animal models of retinal degeneration have now
demonstrated that transplanted photoreceptor cell suspen-
sions can restore visual function, including using PSC-
derived cells albeit with reduced effect. Experiments can be
divided into those with remaining photoreceptors and a
completely absent photoreceptor layer.
Studies in animals with some surviving photoreceptors
have had several key findings. ‘Integration’ (bearing in
mind that some of this is secondary to cytoplasmic transfer
of material with cell rescue rather than actual integration as
mentioned previously) is very dependent on the subretinal
microenvironment and this can affect the survival, mor-
phology and functionality of transplanted cells (reviewed by
Pearson et al. [19]). Both the causative genetic mutation and
stage of the degenerative process are important, meaning
that in clinical translation of this technology in the future the
stage of the disease will be critical. It can also influence the
propensity for cones or rods to successfully ‘integrate’;
cones are more likely to ‘engraft’ in cone-depleted retinas;
however generally cones have been shown to integrate in
significantly lower numbers than rods [42], which poses a
further challenge for possible macular photoreceptor repla-
cement in AMD. Conversely, most mutations causing RP
affect rods primarily and cones die secondarily in the later
stages. Rod transplantation could therefore rescue cones
from dying and has been demonstrated in animal models of
RP [42, 178, 179].
The number of successfully ‘integrating’ cells can be
increased by a variety of treatments to the host environment,
including temporary disruption of the host external limiting
membrane, digestion of disease-associated ECM, especially
chondroitin sulphate proteoglycans using chondroitinase
ABC and also potentially by modulation of glial cell
hypertrophy/activation and matrix metalloprotease activity
[180−182]. Despite these successes, survival rate of trans-
planted cells has been generally low, <5% and reduces with
time. Injection of cells in hydrogels and with the addition of
selected ECM molecules may enhance this. Survival of
donor photoreceptors can also be improved using anti-
apoptotic factors such as X-linked inhibitor of apoptosis
protein (XIAP) and immunosuppression [183, 184] (see
later).
Transplantation in animals with a completely degenerate
outer retina and no remaining photoreceptors (as may be the
case at the fovea in advanced AMD) results in subretinal
cell clumps in close contact with the remaining inner
nuclear layer with limited migration into the host. Synapse
formation, correct orientation with respect to the RPE and
visual responses have however been demonstrated and
related to the number of surviving cells [44, 185, 186].
Photoreceptor survival and connection may be enhanced
when cells are presented subretinally in a range of biode-
gradable synthetic polymers and this is another strategy
being investigated. In actual fact only a relatively small
number of functioning photoreceptors may be needed to
restore vision. Gene therapy experiments in the Gnat1−/−
mouse model of congenital stationary night blindness have
indicated that navigative vision could be detected with only
25,000 functioning rods although approximately 150,000
functioning rods are necessary to generate a reliable sco-
topic ERG response [14]. Exactly how this relates to
humans, especially foveal vision however is very unclear.
There are further barriers that may interfere with successful
visual restoration despite successful cell survival. These
include synaptic connection to the anatomically intact inner
retina, function of the transplanted photoreceptors, and the
synaptic reorganisation of the inner retina that occurs with
very advanced outer retinal atrophy. Indeed in animal
models of advanced outer retinal degeneration caused by
photoreceptor degenerations, synaptic connections between
bipolar cells and amacrine cells are lost [187]. Plasticity
after restoration of an afferent input however may occur and
work with electronic retinal implants in patients with
advanced AMD may be revealing in this context [8].
One other interesting development, which although not
directly related to macular degeneration may have impli-
cations for retinal regeneration, has been a case report of a
free autologous retinal patch transplanted from the
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peripheral retina to the fovea in a patient with a prior retinal
detachment and large macular hole. The patient regained a
visual acuity of 0.6logMAR with gradually improving ret-
inal sensitivity and the authors postulated that the free graft
played some role in retinal regeneration [188]. Further
studies are needed but several surgeons have repeated the
technique with visual benefit (Fig. 9) and further reports are
imminent (personal communication).
Foetal-derived retinal progenitor cells
The exact mechanism of action of human RPC transplan-
tation is unclear at present as discussed previously. They
have rescued photoreceptor death in a number of animal
models and current data suggests it may be chiefly neuro-
protective with growth factor release. The transplanted cells
may also differentiate into, attract or retain neuroprotective
glial cells.
At least two human trials are in progress in the USA
using foetal-derived RPC. ReNeuron (Bridgend, Wales,
UK) have a Phase I/II open-label, dose escalation clinical
trial in progress on 20 patients with RP to evaluate the
safety, tolerability and preliminary efficacy of a subretinal
injection of RPC. jCyte, Inc (Newport Beach, CA, USA)
[189] have a phase 1/2 study of an intravitreal injection of
RPC in patients with RP. Results from both trials are
awaited and if successful these may be extended to patients
with AMD.
Retinal sheets
As mentioned previously foetal retinal sheet transplantation
has been carried out in adults with advanced AMD and ret-
inal sheet transplantation may be a promising strategy espe-
cially in focal disease such as AMD. PSC-derived retinal
organoids are an exciting development in this regard as they
offer the possibility of deriving retinal sheets for transplan-
tation of any developmental stage and in practical quantities.
Takahashi and colleagues have used the ~2mm optic vesicles
derived from hESCs, sectioned them into halves and trans-
planted them into murine and primate models of outer retinal
degeneration [190, 191]. They were able to demonstrate
synaptic connection of the transplanted photoreceptors with
the host in the halves that were transplanted by chance in the
correct orientation, with functional recovery of vision in the
mouse model tested. Future challenges relate to optimising
the delivery and age of transplant, and increasing the size or
number of grafts to improve the overall chance of direct
Fig. 9 66-year-old male patient who developed a large macular hole
with a previous macular involving retinal detachment. Despite a large
diameter internal limiting membrane peel at the initial retinal reat-
tachment surgery, the patient had a persisting macular hole after
otherwise successful surgery (a, b: ILM peel area shown as black line).
The patient underwent a free autologous transplantation of a patch of
retina from just above the superotemporal arcade which was positioned
within the macular hole rim. The day 1 postoperative appearance is
shown in (c), and SDOCT at 2 weeks (d) and 6 weeks (e). Note the
disorganised inner retina within the graft site but more normal
appearing outer retina. SDOCT at 6 weeks following silicone oil
removal showing an intact ellipsoid line (f.) Autofluorescent image
taken at 6 weeks following oil removal (g) showing visible auto-
fluorescence centrally. The patient displayed fixation over the graft
with a visual acuity of logMAR 0.8
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integration. It would be also advantageous to enhance dif-
ferentiation conditions toward a photoreceptor lineage, or
even more specifically a cone lineage rather than inner retinal
cells. Some progress has already been made in this direction
by Zhou and colleagues, who have developed an in vitro
method of differentiation of hESCs in S− and M-cones with
evidence of connecting cilium and outer segment formation
after 60 days [192].
Combined RPE and photoreceptor transplantation
In advanced AMD, both RPE and photoreceptors would
need to be transplanted. RPE often grows adjacent to neural
retina in organoid models, but not as a continuous layer
underlying the developing photoreceptors as occurs in vivo.
It may be possible to develop culture conditions that
encourage RPE growth and it has recently been shown that
0.5% alginate increases RPE growth alongside neural retina
[193]. Alternatively, it may be possible to use tissue engi-
neering to produce a combined transplant of an RPE
monolayer on a biomimetic membrane with an additional
biodegradable scaffold for a photoreceptor layer or retinal
organoid-derived sheet. Similarly, structures including cells
could be printed as a 3D construct [194]. There are as yet no
reports of studies with these approaches.
Choroidal replacement
There has been relatively little investigation into choroidal
replacement in AMD regenerative strategies. Replacement of
healthy RPE may rescue a failing choroid by VEGF and
other growth factor release; however, there is evidence that
choroidal endothelial cells (ECs) are lost early in the patho-
genesis of AMD and as mentioned previously with auto-
logous RPE transplants, choroidal reperfusion is essential for
graft survival. Developing a procedure to replace these cells
would be an important consideration in advanced cases of
AMD—both wet and dry. Human iPSC-derived ECs have
been made and studies with human umbilical vein-derived
ECs suggest that if grown with RPE cells, ECs may acquire
choroidal characteristics [195]. Choroidal ECs have also now
been successfully generated from iPSCs [196, 197]. Decel-
lularised human choroid with preservation of the architecture
of the acellular vascular tubes has been successfully prepared
and successfully seeded with immortalised human and pri-
mate ECs. Potentially a decellularised choroid and BrM may
provide a good surface for iPSC-derived RPE and EC growth
to produce a trilayer graft.
Considerations for immune rejection
The subretinal space is considered to be a relatively
immune-privileged site [161]; however, this depends on the
integrity of the outer retinal blood barrier with an intact RPE
layer [164]. There appears to be a lower propensity to
rejection in subjects with dry AMD compared to wet AMD
[198]. In mice, long-term (but not short term in some dis-
ease models at least [147]) allogeneic photoreceptor trans-
plant survival requires immune suppression [164]; and in
humans the need for long-term immune suppression would
be a major problem in the elderly AMD population
receiving allogeneic transplants. Autologous iPSCs present
a way around this problem but the challenge of creating
patient-specific cells for every person would be a very major
undertaking. Although MHC expression is low in many
types of stem cells, differentiated tissue expresses MHC,
and this expression causes immune rejection. Recently, it
has been shown in primate eyes that matching donors with
recipients for HLA-A, HLA-B, and HLA-DRB1 prevents
an immune response and would mean that banks of HLA-
matched iPSC-derived cells could be usefully created [199].
However, even autologous mouse iPSCs can induce an
immune response, akin to an autoimmune reaction [200]
and only time will tell what will occur in human trans-
plantation. Certainly, minimising surgical trauma will be
important to reducing the activation of innate immunity
(e.g., natural killer and dendritic cells), which is important
on its own in rejection and which can in turn activate
adaptive immune responses. Furthermore, minimising the
use of implanted scaffold materials that can induce
inflammation will be important. Other possible approaches
would be immune tolerance induction by, for example,
reducing MHC class II expression using small-interfering
RNAs and other genetic manipulations of MHC expression.
Host cell rescue
Bearing in mind that many cell types can have cell rescue
effects, and conversely many have the potential for further
differentiation into retinal cell types after transplantation,
there are several cell lines being investigated, which are
specifically being used for host cell rescue and undergoing
clinical trials in patients with a variety of retinal diseases,
including AMD (Table 2). Cells have been injected intra-
vitreally, both in capsulated form and in a suspension.
Neurotech (Cumberland, RI, USA) have used a cell cap-
sule implanted into the vitreous cavity and anchored at the
pars plana containing human RPE cells genetically modified
to overexpress CNTF and encapsulated in a polyethylene
terephthalate scaffold. Phase I and II trials in patients with
AMD (and RP) have shown the device is well tolerated but
evidence of efficacy was less clear and the technology is now
being considered for other applications, including to deliver
anti-angiogenic agents in AMD (NCT02228304).
A wide variety of trials using MSC and other related cells
are in progress. Early phase trials at the University of Sao
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Paulo, using autologous bone marrow-derived stem cells
intravitreally in patients with advanced RP, showed some
efficacy on macular oedema, but after 1 year, the effects
were no longer evident [201]. The University of California
has carried out a phase1 study using intravitreally admi-
nistered autologous CD34+bone marrow stem cells in a
range of retinal diseases, including advanced dry AMD.
Preliminary clinical findings from the ongoing Phase I trial
patients have showed some possible benefit [201−203].
Subretinal injection of human umbilical tissue-derived
cells (hUTCs) (Palucorcel, CNTO-2476) have been eval-
uated in a phase 1/2 trial in 35 patients with advanced dry
AMD. These cells are derived from extraembryonic meso-
derm and can be expanded significantly in vitro but are not
classed as stem cells and do not differentiate into other cell
types. hUTCs have been shown to secrete several key
neurotrophic factors that rescue RPE cell and photoreceptor
function, including phagocytic dysfunction and have also
been shown to promote synaptogenesis via thrombospondin
family proteins [204, 205]. Visual acuity improved in sev-
eral of the treated eyes compared to their fellow eyes but no
changes in geographic atrophy extent or progression were
observed. Retinal detachment occurred in 17% of the
patients although whether these detachments were purely
rhegmatogenous or partly tractional is unclear. Interest-
ingly, the cells were injected using an ab externo approach
to the subretinal space, rather than transvitreal as in most
other trials, using a microcatheter passed transclerally and
advanced under direct view to the paramacular area.
Transchoroidal delivery avoids the problem of reflux of
cells into the vitreous cavity and potentially retinal trauma,
although in the trial retinal perforation occurred in 37% of
patients and the method of delivery is being redesigned for
the next phase of trials.
Preclinical studies using the RCS rat showed that sub-
retinal transplantation of human NPCs derived from human
prenatal cortex resulted in long-term rescue of visual
function [72, 206, 207]. It was thought that their action
related to their ability to phagocytose photoreceptor outer
segments as well as other trophic effects [208]. Stemcells.
inc completed a phase I clinical trial in patients with dry
AMD and a phase 2 trial commenced but was terminated in
2016 (https://clinicaltrials.gov/, #NCT02467634). Trial
results have not been reported and there appears to be no
further studies planned.
Adipose tissue-derived cells have been used in several
trials and are also being used in non-trial situations by
private clinics. Unfortunately, recently three patients were
reported who developed severe visual loss with a variety of
problems, including ocular hypertension, haemorrhagic
retinopathy, vitreous haemorrhage, combined traction and
rhegmatogenous retinal detachment, and lens dislocation
after intravitreally delivered cells [209].
Conclusion
The dream of replacing or rescuing old, dead or dying cells
with new young ones is appealing and the developments in
the field are very exciting. However, the path to an effective
safe cellular therapy that can be used routinely in patients
for late-stage AMD is likely to be a long one. IPSC
technology and 3D retinal organoid production have been
huge recent steps in this path, but several aspects of cellular
therapies outlined in this review need further refinement.
The optimum cell sources and age of cells used for
transplant need to be identified, cells have to be produced in
the numbers required in GMP and Xeno-free conditions,
and they then need to be sorted so that the desired cell types
are isolated before transplantation. Cell delivery needs
further thought as well. Cell sheet transplants require large
retinotomies with their associated risks of PVR and sub-
retinal fibrosis, which could not only cause surgical com-
plications but also affect integration of the graft. Fibrosis
has been a major challenge in several transplant disciplines
and lessons could be learned across disciplines. Cell sus-
pensions have problems of cell death during delivery, reflux
during injection and a less than perfect cellular distribution
after injection aside from RPE adhesion problems, all
potentially aided by tissue engineering approaches. Cellular
integration and survival after delivery also need improving
perhaps aided by pro-survival agents added to the trans-
planted cells including potentially the use of combined gene
therapy.
Preclinical testing would be easier to interpret if there
were representative, near human size and accepted animal
models of AMD. The commonly used model of the RCS rat
is rescued by a wide variety of disparate cell sources and
does not represent AMD very closely. Rabbit and pig
models, although having visual streaks, lack foveas and in
the case of rabbits are merangiotic, while primate models, as
well as having ethical concerns and expense, do not have
the problems of cell adherence to BrM seen in aged human
subjects.
Unmasked fellow eye control phase I studies have
established the safety of many treatments, but evidence of
unequivocal, reproducible and sustained efficacy needs to
be demonstrated. Indeed, there are several limitations to
using these studies to suggest efficacy in terms of asym-
metrical disease and progression, protective cytokine
release with surgery (albeit usually short term) and learning
effects in terms of eccentric fixation in worse fellow eyes
[210, 211] and randomised masked studies are required to
prove effect. The trials that have been conducted to date
however have been essential first steps. Theory and
laboratory work can only advance in the field so far and it is
hoped these early trials are the first steps to proven effective
and safe therapies.
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